ReachRxResearch
Home
Research
Sign Up
Prognostic Thresholds of Tricuspid Regurgitation in Transthyretin Amyloid Cardiomyopathy
Back to Research Hub
  1. Home
  2. Research Hub
  3. Prognostic Thresholds of Tricuspid Regur…

Prognostic Thresholds of Tricuspid Regurgitation in Transthyretin Amyloid Cardiomyopathy

JAMA Cardiology·August 31Open Access
Cardiac & Cardiovascular SystemsPractice changingTransthyretin Amyloid CardiomyopathyTricuspid RegurgitationMulticenter Prospective Cohort StudyEchocardiographyOlder AdultVyndamaxAcoramidisPatisiranTafamidisVutrisiran

Summary

View source

What was studied

This international multicenter cohort study (8 centers across Austria, Italy, Germany, and the Netherlands; January 2016–February 2026) derived and validated disease-specific echocardiographic TR severity thresholds in 1,124 newly diagnosed ATTR-CM patients, comparing their prognostic performance for all-cause mortality and heart failure hospitalization (HFH) against current ESC/EACTS, AHA/ACC, ASE, and TVARC grading schemes.

Key findings

Spline-derived thresholds classified 29.7% of patients (n=334) as high or extreme risk, versus only 11.6% (n=130) with guideline-defined severe TR (P<0.001). The new framework carried the highest adjusted hazard ratios for mortality (HR 1.41; 95% CI 1.23–1.62) and HFH (HR 1.31; 95% CI 1.12–1.54), with extreme-risk patients showing 4- to 6-fold higher mortality vs. low-risk. Time-dependent AUC was consistently superior to ESC/EACTS–AHA/ACC at all time points; in the non-amyloid HF cohort (n=364), the framework offered no discriminatory advantage.

Study limitations

- Derivation and validation cohorts differed in several baseline characteristics (e.g., ATTR subtype distribution, ATTR-specific therapy use, SGLT-2i use), which may limit generalizability. - Missing quantitative TR data required median imputation by local TR grade, though a complete-case sensitivity analysis was performed. - The atrial functional TR subgroup was defined by a pragmatic proxy (right atrial dilatation + normal RV size) rather than a validated dedicated algorithm.

Clinical implications

Standard guideline TR grading misses nearly two-thirds of ATTR-CM patients who carry significant prognostic risk; clinicians should consider applying quantitative thresholds (VCW ≥3 mm, EROA ≥0.15 cm², RegVol ≥10 mL for intermediate risk) specific to ATTR-CM's restrictive low-flow physiology. These disease-specific cut-offs should not be applied to non-amyloid heart failure populations, where conventional schemes perform better.

Caveats

  • Tafamidis brand tag 'Vyndamax' applied as the most common drug in this cohort (95.5% of ATTR-specific therapy); acoramidis brand name (BridgeBio's 'Attruby') was not tagged as a brand due to very low use (n=2) and uncertainty about approval status at time of data collection.
  • The cohort is predominantly older adult males (median age 80, 76.9% male) from European tertiary centers, which may limit generalizability to younger, female, or non-European ATTR-CM populations.
  • The 'practice_changing' flag is applied because this framework reclassifies a substantially larger proportion of ATTR-CM patients as high/extreme risk compared to all current guidelines; however, prospective interventional validation (e.g., whether reclassification changes treatment decisions or outcomes) has not yet been demonstrated.

Related Questions

Explore related topics

What are the best echocardiographic parameters to grade tricuspid regurgitation severity in ATTR cardiomyopathy?How does tricuspid regurgitation affect prognosis in transthyretin amyloid cardiomyopathy patients on tafamidis?Should ATTR-CM patients with moderate TR by guideline criteria be reclassified as higher risk using quantitative echo thresholds?

Publication Details

Year
2026
Journal
JAMA Cardiology
Sample Size
n=1,124
Source
View article
Keep scrolling
More content below.
Up Next